Invokana, Invokamet, Invokamet XR, Canagliflozin Related Injuries

On May 16, 2017, the FDA concluded that the Type 2 diabetes medication Canagliflozin (Invokana, Invokamet and Invokamet XR) causes an increased risk of leg and foot amputations. The FDA now requires the most prominent black Boxed Warning to be added to the Canagliflozin drug labels describing this risk. Two large clinical trials concluded that leg and foot amputations occurred about twice as often in patients treated with Canagliflozin versus those patients treated with a placebo.

Duncan Garnett is actively investigating Canagliflozin cases on behalf of patients across the nation who have suffered an amputation as a result of taking the popular diabetes drug.